TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Poly Juvenile Idiopathic Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* subjects who had successfully completed the previous Dose Finding Study and were fully compliant to the inclusion/exclusion criteria described in the previous DSC/08/2357/36~Exclusion Criteria:~* patients with fever related to JIA or other systemic features of JIA during 12 months before entering the study~* active bacterial or mycotic infection requiring antimicrobial treatment~* episode of macrophage activation syndrome over the last 6 months~* baseline prolongation of QT/QTc interval, use of concomitant medications that prolong the QT/QTc interval or history of additional risk factors for TdP.~* clinically significant cardiovascular disease~* clinically significant illness i.e. any condition that in the opinion of the Investigator places the patient to unacceptable risk for adverse outcome if he/she were to participate in the study~* psychiatric illness/social situation that would limit compliance with study medication and protocol requirements~* inherited metabolic diseases~* presence of malignancy~* pregnancy or lactation~* positive blood test for HIV~* active EBV infection, active B and/or C hepatitis~* platelet count \<100x10(9)/L

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Givinostat (Type: EXPERIMENTAL): Patient received the dose of 0.75 mg/kg BID from December 28th, 2011 to January 27th, 2014

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Role of Biomarkers in Muscle Pain and Joint Pain in Patients With Solid Tumors Receiving Paclitaxel

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Solid malignancy of any type~* Patients must be scheduled to receive their first dose of paclitaxel at Vanderbilt-Ingram Cancer Center~  * Any paclitaxel-containing regimen or dosing schedule is allowed~PATIENT CHARACTERISTICS:~* Not pregnant~* Accessible for follow-up~* Able to submit urine samples~* Able to complete questionnaires~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paclitaxel-Induced Myalgias/Arthralgias (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of Ablathermy Focused Ultrasound (USF) of Breast Tumors Before Mastectomy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Invasive Breast Carcinoma with histologically confirmed hormone receptor analysis, the grade of the tumor, the expression of Her-2.~* Lesion classified T1-T2-T3 unifocal or multifocal with or without associated microcalcifications~* Lesion recognizable and identifiable in MRI~* Indication of mastectomy with or without axillary~* Lesion located more than 10 mm from the skin, the nipple and pectoralis major~* No cons-indication to MRI (pacemaker)~* Women whose age is ≥ 18 years~* If premenopausal patient: patient contraceptives~* Patient has signed informed consent~* Affiliation to a social security scheme~Exclusion Criteria:~* Tumor-TD T4B classified or non-palpable lesion~* If age \<70 years: no indication of adjuvant chemotherapy and neoadjuvant~* MRI lesions have not been identified, located within 10 mm of the skin and pectoral muscle, greater than 25 mm diameter~* Inability to hold still in the prone position, arms extended, for 30 minutes~* Contraindication to MRI~* Patient deprived of liberty and major subject of a measure of legal protection or unable to consent~* Patient participating in another interventional clinical trial within 30 days prior to baseline and during the trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ablathermy focused ultrasound (Type: EXPERIMENTAL): ablathermy focused ultrasound

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Noninvasive Blood Glucose Monitoring Method Based on Imaging of the Eye

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Diabetes Type 1 and 2 and can be verified by the principal investigator~Exclusion Criteria:~* Patients with any disease or abnormality of the eye~* Patients who are mentally incapacitated, cognitively impaired or with severe psychological disorders and cannot sign consent on their own

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- New device for OPTICAL determination of blood glucose level (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Structural and Functional Brain Reorganization in Neuropathic Pain: Basal State of Local Cerebral Blood Flow and Functional Connectivity

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria for patients :~* major~* with nervous pain : chronic or peripheric~* treatment not stable opioid since one week~* signed consent~Inclusion Criteria for witnesses :~* major~* without chronic pain~* signed consent~Exclusion Criteria for 2 groups :~* severe psychiatric history~* presence of an active nervous lesion~* subject with morphine treatment~* contraindication to MRI scan

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- peripheric nervous lesion (Type: EXPERIMENTAL): MRI scan
- medullar or encephalic lesion (Type: EXPERIMENTAL): MRI scan
- control group (Type: OTHER): MRI scan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Adolescent and Young Adult Survivor Transition

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completed cancer treatment within the past three months of all cancer types and stages~* Signed, written consent~Exclusion Criteria:~* Have not completed cancer treatment within the past three months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Survivor Distress (Type: EXPERIMENTAL): This intervention will use the NCCN Distress Screening Thermometer to score each participant on their level of distress. Depending on the score the intervention will be tailored to the participant based on the Overview of Evaluation and Treatment Schema DIS-4 per the NCCN Distress Guidelines V1.0, 2016.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) Over the Brain on the Neurotransmitter Binding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy people~* 18-50 yrs old~* Right handedness~* Written informed consent~Exclusion Criteria:~* Previous medical diseases such as seizure, stroke, diabetes, hypertension.~* Taking any drugs~* Smoker~* Pregnancy~* Contraindication of PET or MRI~* Stroke or any tumor in MRI~* Metals objects in the head or eyes~* Cardiac pacemaker or cochlear implant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- High frequency (10Hz) rTMS (Type: EXPERIMENTAL): \<high frequency rTMS parameters\> Intensity: 120% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 10Hz; Number of total stimuli: 750; Coil orientation: tangential to scalp
- Low frequency (1Hz) rTMS (Type: EXPERIMENTAL): \<low frequency rTMS parameters\> Intensity: 120% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1200; Coil orientation: tangential to the scalp
- Sham rTMS (Type: SHAM_COMPARATOR): \<Sham rTMS parameters\> Intensity: 120% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1200; Coil orientation: perpendicular to scalp

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has signed and dated approved informed consent form.~* There is confirmed laboratory diagnosis of HIV infection (positive ELISA HIV antibody test confirmed by Western blot, p24 antigen assay, quantitative HIV-1 RNA assay, or HIV culture).~* The patient is at least 18 years of age.~* ART-naïve, lopinavir/ritonavir susceptible on genotypic testing, CCR5-tropic virus on Trofile testing (ESTA).~* Negative pregnancy test within 72 hours prior to start of study for women of childbearing potential.~* Females of childbearing potential and males must utilize effective barrier contraception.~* HIV RNA greater than 1,000 copies per mL at entry.~* Liver enzymes (AST, ALT) \< 3 times the upper limit of normal.~Exclusion Criteria:~* Patients who are pregnant or breast-feeding.~* Active alcohol or substance abuse sufficient, in the Investigator's opinion that makes compliance to the study protocol unlikely.~* Suspected or active HIV-related opportunistic infection or condition requiring acute therapy within 30 days of entry into the trial.~* Patients on therapy for hepatitis B.~* Patients with hepatitis B surface antigen, or any evidence of active hepatitis B such as positive hepatitis B DNA and/or presence of hepatitis e antigen or e antibody.~* Acute hepatitis B or C within 60 days of entry.~* Patients harboring preexistent co-receptor CXCR4 tropic or dual-or mixed-tropic HIV.~* Patients harboring HIV resistant to lopinavir/ritonavir on genotypic testing.~* The presence of decompensated heart failure, myocardial infarction within 1 year, bypass surgery, severe vascular disease, or active hepatobiliary disease.~* Concomitant use of rifampin, ergot derivatives (i.e. dihydroergotamine, ergotamine), cisapride, lovastatin, simvastatin, triazolam, orally administered midazolam, carbamazepine, phenytoin, St. John's wort, ketoconazole, itraconazole, clarithromycin, telithromycin, amiodarone, bepridil, flecainide, propafenone, quinidine, voriconazole or nefazodone.~* Patients with concomitant diagnosis of malignancy or cancer other than basal cell carcinoma within the past 5 years.~* Concomitant use of investigational agents including the use of any investigational vaccines.~* Any other clinical conditions or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for study, or unable to comply with the dosing requirements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- open label single arm (Type: EXPERIMENTAL): Drug: lopinavir/ritonavir plus maraviroc

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Ferrisat vs Placebo in Anemia Associated to Inflammatory Bowel Disease During Anti-TNF Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than 18 years~* Crohn's disease or Ulcerative Colitis defined according to the usual endoscopic, histological, and radiological criteria~* Under anti-TNF therapy or indication for starting an anti-TNF therapy~* Anemia defined according to World Health Organization (Hemoglobin under 13g/dl for man and Hemoglobin under 12g/dl for woman)~* Iron deficiency anemia defined as:~* Ferritinemia under 100 if C-Reactive Protein under normal value OR - Ferritinemia between 30 and 100 if C-Reactive Protein above normal value~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferrisat (Type: ACTIVE_COMPARATOR): Infusion of Ferrisat (50mg/ml) at inclusion under usual practices
- Placebo (Type: PLACEBO_COMPARATOR): Infusion of placebo at inclusion visit

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: rhPTH Therapy for Low Turnover Bone Fragility

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* :patients with history of increased bone fragility by BMD criteria (T score \> -1). In addition, the subjects will be enrolled only if they have clear evidence of low bone turnover as indicated by low normal levels of biochemical markers of bone turnover and finding of low bone turnover on bone biopsy. Each subject and his/her treating physician will have agreed that the rhPTH is the best treatment for the patient. Treatment with rhPTH will be considered only if the bone histomorphometry reveals a low turnover state and excludes other known forms of bone disease such as osteomalacia.~Exclusion Criteria:~* Subjects who are pregnant or younger than 20 will be excluded. Subjects cannot have osteoporosis

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rhPTH (Type: EXPERIMENTAL): Subjects will be treated rhPTH for 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Glitazones and Endothelial Function (GATE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All patients (both men and women) considered for participation in GATE study have to be non-insulin dependent diabetics (according to Canadian Diabetes Association criteria, namely a fasting serum glucose ≥ 7.0 mmol/L on two occasions, a casual glucose ≥ 11.1 mmol/l with symptoms, or a 2-h post-oral glucose tolerance test glucose of ≥ 11.1 mmol/l) with unsatisfactory glycemic control on oral therapy (HbA1c 6-10%).~Exclusion Criteria:~* Exclusion criteria includes, congestive heart failure (NYHA class III \& IV or ejection fraction less than 35%), poorly controlled hypertension (blood pressure \> 160/90), hypercholesterolemia (total cholesterol \> 6.2 mmol/l), hypertriglyceridemia (triglycerides \> 4.0 mmol/l), poor or excellent control of DM (HgA1c \<6 % or HbA1c \> 10% respectively), known diabetic retinopathy, age at diagnosis of diabetes less than 25 years, current participation in another clinical trial and contraindications to glitazones therapy, including renal (creatinine \> 200 micromol/ L) or hepatic (ALT \> 2.5 times the upper limit of normal) impairment and/ or known intolerance to glitazones. Patients must be stable on medications that affect endothelial function for more than one month. This includes ACE-inhibitors, angiotensin receptor blockers, statins, calcium channel blockers, hormone replacement therapy and anti-oxidant vitamins, including folates. Patients on insulin will be excluded. Patients in whom it is felt that attainment of better glucose control is required within 3 months will also be excluded. Patients with stable coronary disease will be eligible for the study as long as they are \> one month post myocardial infarction, percutaneous intervention or bypass surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PREvention of VENous ThromboEmbolism Following Radical Prostatectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men 18-100 years of age with histologically confirmed prostate cancer of any stage undergoing RP~* Patients who would have otherwise been eligible to receive routine post-RP care~Exclusion Criteria:~* Active treatment for VTE~* Patients judged by patients' urologist, primary care doctor, or in the preoperative evaluation center (PEC) to be unsafe to forgo pharmacologic prophylaxis or systemic anticoagulation postoperatively (whether or not patients are on systematic anticoagulation for indications other than VTE)~* Known adverse reactions to heparin (heparin-induced thrombocytopenia or any allergy)~* Epidural analgesia~* Spinal anesthesia~* Participation in a different trial that increases a patient's risk of VTE

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Subcutaneous Heparin (Type: EXPERIMENTAL): Patients randomized to the pharmacologic VTE prophylaxis arm will receive a dose of subcutaneous heparin 5,000 units prior to incision, and subcutaneous heparin 5,000 units every 8 hours after surgery until discharge.
- Control (Type: NO_INTERVENTION): Patients randomized to the control arm will receive routine care with intermittent pneumatic compression devices.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Pre-incisional Intravenous Ibuprofen to Reduce Postoperative Pain and Opioid Dependence After Posterior Cervical or Lumbar Instrumented Spine Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients older than 18 years of age~* Able to give consent~* Diagnosed with spondylosis, stenosis, and/or instability of the cervical spine~* Diagnosed with spondylosis, stenosis, and/or instability of the lumbar spine~* Require a posterior decompression with internal fixation~* Likely to complete the trial~Exclusion Criteria:~* Patients with previous surgery at the treated spine segment~* Women who are pregnant or plan to become pregnant during the study period Renal/liver disease~* Anemia; coagulopathy~* Thrombocytopenia (\<30,000)~* Coronary artery disease~* Previous coronary artery bypass graft (CABG)~* Patients taking Coumadin, Plavix, Lithium, or ACE-inhibitors plus Lasix; non-steroidal anti-inflammatory drug (NSAID) hypersensitivity~* Gastric ulcers~* Recent stroke~* Traumatic brain injury, or intracranial surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intravenous (IV) ibuprofen (Type: ACTIVE_COMPARATOR): 800mg IV ibuprofen before incision, followed by four total scheduled doses of IV ibuprofen every six hours for 24 hours, in addition to whatever narcotic or other pain control regimens prescribed by the treating physician to control postoperative pain.
- Intravenous (IV) normal saline (Type: PLACEBO_COMPARATOR): 800mg normal saline before incision, followed by four total scheduled doses of IV ibuprofen every six hours for 24 hours, in addition to whatever narcotic or other pain control regimens prescribed by the treating physician to control postoperative pain.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues